Back to news

Cogent Biosciences Slides as Investors Digest Recent Results and Await Key FDA Decision

Investivoq PriceTracker

Cogent Biosciences (COGT) is down 7.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a pullback after last week’s quarterly update, which showed a wider net loss and a sharp increase in general and administrative spending as the company prepares for a potential launch of bezuclastinib. With no clear new negative company announcement tied to today, the decline could also reflect traders reducing risk ahead of the November 30, 2026 FDA decision for bezuclastinib in GIST and broader biotech weakness.

Details:

  • The company’s November 5, 2026 earnings release showed third-quarter net loss widened to $111.4 million from $80.9 million a year earlier.
  • General and administrative expense rose to $42.1 million from $14.4 million, largely tied to commercial-readiness investments for a possible bezuclastinib launch.
  • Management said cash, cash equivalents, and marketable securities were $791.1 million as of September 30, 2026, which it expects will fund operations into late 2028, so the move does not appear to be driven by an immediate financing concern.
  • The company remains close to a major regulatory catalyst, with a November 30, 2026 PDUFA date for bezuclastinib in GIST, which can increase volatility as investors reposition ahead of a binary event.

    • Sources:

    SEC, Cogent Biosciences, AAII

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $COGT Insider Trading Activity

    COGT Insider Trades

    $COGT insiders have traded $COGT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $COGT stock by insiders over the last 6 months:

    • ARLENE MORRIS has made 0 purchases and 2 sales selling 45,510 shares for an estimated $1,689,492.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive COGT Data Alerts
    Get market-moving data, filings, and signals for COGT in real time.
    Sign Up

    $COGT Hedge Fund Activity

    We have seen 179 institutional investors add shares of $COGT stock to their portfolio, and 136 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEERFIELD MANAGEMENT COMPANY, L.P. removed 4,037,799 shares (-44.6%) from their portfolio in Q2 2026, for an estimated $156,262,821
    • POLAR CAPITAL HOLDINGS PLC added 3,232,905 shares (+inf%) to their portfolio in Q2 2026, for an estimated $125,113,423
    • RTW INVESTMENTS, LP removed 3,149,654 shares (-57.7%) from their portfolio in Q2 2026, for an estimated $121,891,609
    • HOLOCENE ADVISORS, LP removed 2,217,364 shares (-98.5%) from their portfolio in Q2 2026, for an estimated $85,811,986
    • GOLDMAN SACHS GROUP INC removed 2,145,421 shares (-48.4%) from their portfolio in Q2 2026, for an estimated $83,027,792
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,449,300 shares (+inf%) to their portfolio in Q2 2026, for an estimated $56,087,910
    • PRICE T ROWE ASSOCIATES INC /MD/ added 1,439,912 shares (+44.8%) to their portfolio in Q2 2026, for an estimated $55,724,594

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.